Moderate Psoriasis – Pipeline Insight, 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Moderate
Psoriasis – Pipeline Insight, 2018”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

This report offers a comprehensive insight of the pipeline (under
development) therapeutics scenario and growth prospects across Moderate
Psoriasis development. The report provides detailed coverage of the
pipeline landscape for this mechanism of action, equipped with data from
multiple sources with complete pipeline analysis by developmental stage,
associated indications, route of administration and molecule type.

Scope

  • The report provides a snapshot of the pipeline development for
    Moderate Psoriasis
  • The report covers pipeline activity across the complete product
    development cycle i.e. clinical, pre-clinical and discovery stages for
    Moderate Psoriasis
  • The report provides pipeline product profiles which includes product
    description, developmental activities, licensors & collaborators and
    chemical information
  • Provides pipeline assessment by monotherapy and combination therapy
    products, stage of development, route of administration, and molecule
    type for Moderate Psoriasis
  • The report also covers the dormant and discontinued pipeline projects
    related to Moderate Psoriasis

Key Topics Covered

1. Report Introduction

2. Moderate Psoriasis Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Moderate Psoriasis

4. Comparative Analysis

5. Products in Clinical Stage

5.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

6.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

8.1 Drug Name : Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Featured

  • AbGenomics International
  • ADC Therapeutics Sarl
  • Almirall
  • AstraZeneca Plc
  • Avexxin AS
  • Boehringer Ingelheim GmbH
  • Celgene Corporation
  • Convoy Therapeutics
  • Crescendo Biologics Limited
  • Delenex Therapeutics AG
  • Eli Lilly and Company

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/fdqvtd/moderate?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs
, Psoriasis
Drugs